A5075973822- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- PI3K/AKT/mTOR signaling in cancer
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Ovarian cancer diagnosis and treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- interferon and immune responses
- Cancer-related molecular mechanisms research
- Immunotherapy and Immune Responses
- Cytomegalovirus and herpesvirus research
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
First Affiliated Hospital of Xiamen University
2023-2025
Geological Exploration Institute of Shandong Zhengyuan
2025
Xiamen University
2024
Shantou University
2024
Cancer Hospital of Shantou University Medical College
2024
BioMimetic Systems (United States)
2022
Biosensores (Spain)
2022
Manchester Airport
2013
Abstract Purpose: To investigate the efficacy and safety of novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments. Patients Methods: Histologically confirmed FL disease progression after receiving second-line or greater therapy were enrolled. Linperlisib was administered 80 mg every day, a 28-day cycle until intolerable toxicity occurred. The primary outcome for study objective response...
Abstract Background Disease progression within 24 months (POD24) significantly impacts overall survival (OS) in patients with follicular lymphoma (FL). This study aimed to develop a robust predictive model, FLIPI-C, using machine learning approach identify FL at high risk of POD24. Methods A cohort 1,938 (FL1-3a) from seventeen centers nationwide China was randomly divided into training and internal validation sets (2:1 ratio). XGBoost utilized construct the POD24-predicting which internally...
Aim: To elucidate the clinicopathological and prognostic values of interferon regulatory factor (IRF) family genes in acute myeloid leukemia (AML). Patients & methods: Differential expression analysis survival from several reliable databases were conducted further validated using patients with AML. Results: The level IRF1/2/4/5/7/8/9 AML was upregulated, while IRF3/6 downregulated. High IRF1/7/9 indicated a worse overall rate. Conclusion: Overexpression may be associated poor AML, suggesting...
Follicular lymphoma (FL) is an immune-responsive tumor with spontaneous remission. T cells play a pivotal role in the anti-lymphoma immune response. However, dynamics of during treatment, their impact on FL clinical outcomes, and risk factors contributing to T-cell cytopenia remain largely unexplored. subsets peripheral blood patients at diagnosis, 2–4 cycles after 6 as well healthy individuals were detected by flow-cytometry. The predictive effects for early progression risks analyzed....
<div>AbstractPurpose:<p>To investigate the efficacy and safety of novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments.</p>Patients Methods:<p>Histologically confirmed FL disease progression after receiving second-line or greater therapy were enrolled. Linperlisib was administered 80 mg every day, a 28-day cycle until intolerable toxicity occurred. The primary...
<p>Subgroup analysis of (A) ORR, (B) DOR and (C) PFS confirmed by investigator</p>
<p>Comparison of the concentrations serum markers measured in patients with and without a response to linperlisib</p>
<p>Serum cytokine concentrations before and during treatment</p>
<p>Subgroup analysis of (A) ORR, (B) DOR and (C) PFS confirmed by investigator</p>
<p>Comparison of the concentrations serum markers measured in patients with and without a response to linperlisib</p>
<p>Serum cytokine concentrations before and during treatment</p>